History

NovaSterilis was incorporated in the State of New York in 2000. The original process, which has evolved to today’s robust technology, was demonstrated in 2002. In 2003, NovaSterilis built its Nova2200™ commercial prototype. The prototype was used to show the scalability of the technology to commercial size chambers.

In 2006, NovaSterilis sold its first Nova2200™ to CBC/CTS of Dayton, Ohio. The USPTO also issued NovaSterilis a patent that same year. The evolution of the patented technology has continued with several patents pending associated with the sterilization process. NovaSterilis has continued to demonstrate its technology in the applications of pharmaceuticals, large and small molecule drugs, vaccines, engineered tissues, low density polymers, and more.

In 2007, NovaSterilis was the sole small business recipient for the President's Green Chemistry Challenge Award, given by the United States EPA. LifeCell Corp, a leader in regenerative medicine licences the technology for research and development purposes.

In 2009, TissueNet (Orlando FL) becomes the first tissue bank and commercial entity to use NovaSterilis Supercritical CO2 Terminal Sterilization technology to produce SAL6 sterile products. TissueNet produces a very high quality, extremely clean, SAL6 sterile allograft product that is very popular with surgeons. A leading pharmaceutical company licenses SCCO₂ terminal sterilization for the purpose of sterilizing active pharmaceutical ingredients, inactive ingredients, unfinished and finished products. In July, USPTO grants the patent - Inactivating Organisms Using Carbon Dioxide at or Near its Supercritical Pressure and Temperature Conditions.

In 2010, Alamo Tissue Service/Precision Allograft Services (San Antonio TX) licenses technology, later in the year they validate soft tissue allograft products and begin sales. NovaSterilis and CC Chu Ph.D. (Cornell) receive Metropolitan Development Assoc. grant to explore the feasibility of terminally sterilizing bioresorbable materials. (sutures, polymers) This study produced favorable outcomes, Dr. Chu and NovaSterilis agree to pursue further research. Australian Biotechnologies PTY LTD receives Australian Government Dept. of Health and Ageing Therapeutic Goods Administration approval to manufacture for sale human tissue product. This product, a cortical and cancellous bone crunch product for bone repair, is the first product utilizing NovaSterilis SCCO₂ terminal sterilization technology. Allograft Innovations (Gainesville FL) licenses technology, becomes the second tissue bank to validate the process and launch supercritical co2 sterilized product. August USPTO Combined Use of an Alkaline Earth Metal Compound and a Sterilizing Agent to Maintain Osteoinduction Properties of a Demineralized Bone Matrix

In 2011, NovaSterilis and CC Chu Ph.D. receive phase 1 NIH grant to build on the proof of concept work performed through the MDA grant. NovaSterilis installs a Nova2200 unit at Natick Soldier Research Development Engineering Center (NSRDEC). This collaboration with the Combat Feeding Program is to develop healthier, better tasting, and longer lasting Meals Ready to Eat (MRE).